<?xml version="1.0" encoding="UTF-8"?>
<fn-group>
 <fn fn-type="other">
  <p>
   <bold>ClinicalTrials.gov identifier:</bold> NCT02509494, 
   <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02509494" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT02509494</ext-link>
  </p>
 </fn>
 <fn fn-type="COI-statement">
  <p>
   <bold>Declaration of conflicting interests:</bold> The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
  </p>
 </fn>
 <fn fn-type="financial-disclosure">
  <p>
   <bold>Funding:</bold> The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This project was funded by the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement no. 115854. This Joint Undertaking receives support from the European Unionâ€™s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Association.
  </p>
 </fn>
 <fn fn-type="other">
  <p>
   <bold>Research ethics and patient consent:</bold> The EBOVAC-Salone study was approved by the London School of Hygiene &amp; Tropical Medicine Ethics Committee and the Sierra Leone Ethics and Scientific Review Committee. All participants or parents/guardians of minors participating in the study provided written consent. In the case of illiterate participants, this consent was witnessed by an impartial witness.
  </p>
 </fn>
 <fn fn-type="other">
  <p>
   <bold>Trial registry name:</bold> Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo During Implementation of Stage 1 and 2 (EBOVAC-Salone).
  </p>
 </fn>
</fn-group>
